DRW Securities LLC purchased a new position in argenx SE (NASDAQ:ARGX - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 1,269 shares of the company's stock, valued at approximately $780,000.
Other institutional investors have also made changes to their positions in the company. Whipplewood Advisors LLC acquired a new position in shares of argenx during the 4th quarter worth $37,000. Global Retirement Partners LLC lifted its position in shares of argenx by 369.2% in the fourth quarter. Global Retirement Partners LLC now owns 61 shares of the company's stock worth $38,000 after buying an additional 48 shares during the last quarter. FIL Ltd acquired a new position in argenx during the fourth quarter valued at approximately $38,000. Jones Financial Companies Lllp lifted its stake in shares of argenx by 1,016.7% in the fourth quarter. Jones Financial Companies Lllp now owns 67 shares of the company's stock worth $41,000 after buying an additional 61 shares during the last quarter. Finally, Whittier Trust Co. of Nevada Inc. boosted its holdings in shares of argenx by 78.6% during the 4th quarter. Whittier Trust Co. of Nevada Inc. now owns 75 shares of the company's stock worth $46,000 after buying an additional 33 shares during the period. 60.32% of the stock is currently owned by institutional investors and hedge funds.
argenx Price Performance
Shares of ARGX traded down $6.67 during trading hours on Tuesday, hitting $599.72. The stock had a trading volume of 306,709 shares, compared to its average volume of 308,195. The stock has a market capitalization of $36.44 billion, a price-to-earnings ratio of -681.50 and a beta of 0.60. The company's fifty day moving average is $606.57 and its two-hundred day moving average is $604.95. argenx SE has a 52 week low of $352.77 and a 52 week high of $678.21.
argenx (NASDAQ:ARGX - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The company reported $1.58 earnings per share for the quarter, topping the consensus estimate of $0.98 by $0.60. The company had revenue of $761.22 million during the quarter, compared to analyst estimates of $678.52 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. Equities analysts predict that argenx SE will post 3.13 EPS for the current fiscal year.
Analysts Set New Price Targets
A number of equities research analysts have issued reports on ARGX shares. William Blair restated an "outperform" rating on shares of argenx in a report on Friday, February 28th. Sanford C. Bernstein upgraded argenx from a "market perform" rating to an "outperform" rating in a research note on Monday, March 17th. Oppenheimer lifted their price target on argenx from $675.00 to $704.00 and gave the stock an "outperform" rating in a research report on Friday, February 28th. Wells Fargo & Company raised their price objective on shares of argenx from $723.00 to $741.00 and gave the stock an "overweight" rating in a research note on Friday, February 28th. Finally, HC Wainwright reiterated a "buy" rating and set a $720.00 target price on shares of argenx in a research note on Tuesday, April 8th. Three analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $690.33.
View Our Latest Analysis on ARGX
About argenx
(
Free Report)
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.
Further Reading
Before you consider argenx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and argenx wasn't on the list.
While argenx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
